MeSH term
Frequency | Condition_Probility | Humans | 185 | 0.0 |
Electroencephalography | 2 | 0.0 |
English Abstract | 5 | 0.0 |
Binding Sites | 6 | 0.0 |
Calcium/*physiology | 2 | 1.0 |
Cell Line, Tumor | 2 | 0.0 |
Databases, Factual | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 6 | 1.0 |
Melanoma | 2 | 2.0 |
Models, Molecular | 11 | 0.0 |
Protein Binding | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 124 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 29 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Adolescent | 16 | 0.0 |
Biological Markers/cerebrospinal fluid | 3 | 11.0 |
Child | 6 | 0.0 |
Child, Preschool | 7 | 0.0 |
Comparative Study | 40 | 0.0 |
Female | 80 | 0.0 |
Infant | 12 | 0.0 |
Interleukin-6/cerebrospinal fluid | 2 | 18.0 |
Male | 76 | 0.0 |
Phosphopyruvate Hydratase/cerebrospinal fluid | 3 | 60.0 |
S100 Proteins/cerebrospinal fluid | 6 | 66.0 |
Amino Acid Sequence | 18 | 0.0 |
Animals | 62 | 0.0 |
Calcium-Binding Proteins/chemistry/genetics/*metabolism | 2 | 33.0 |
Models, Biological | 2 | 0.0 |
Molecular Sequence Data | 20 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Repressor Proteins/chemistry/genetics/metabolism | 2 | 11.0 |
Sequence Alignment | 5 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Adult | 61 | 0.0 |
Aged | 44 | 0.0 |
Biological Markers/analysis | 6 | 0.0 |
Brain Chemistry | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Middle Aged | 51 | 0.0 |
Predictive Value of Tests | 17 | 0.0 |
*S100 Proteins | 36 | 46.0 |
Severity of Illness Index | 6 | 0.0 |
Blotting, Western | 5 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Calcium-Binding Proteins/chemistry/*metabolism | 3 | 23.0 |
*Cell Cycle Proteins | 10 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
EF Hand Motifs | 2 | 18.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Ligands | 4 | 0.0 |
Nerve Growth Factors/*metabolism | 7 | 8.0 |
Plasmids/metabolism | 3 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Rats | 15 | 0.0 |
S100 Proteins/*metabolism | 9 | 16.0 |
Aged, 80 and over | 18 | 0.0 |
Apoptosis | 2 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Glycosylation End Products, Advanced/*metabolism | 2 | 4.0 |
Immunoblotting | 2 | 0.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Pilot Projects | 7 | 1.0 |
Statistics, Nonparametric | 5 | 0.0 |
Organ Specificity | 3 | 0.0 |
Calcium-Binding Proteins/*blood | 13 | 50.0 |
Case-Control Studies | 11 | 0.0 |
Laser-Doppler Flowmetry | 2 | 5.0 |
Nerve Growth Factors/*blood | 30 | 83.0 |
Gestational Age | 4 | 0.0 |
Pregnancy | 8 | 0.0 |
S100 Proteins/*blood | 33 | 78.0 |
Base Sequence | 4 | 0.0 |
Circular Dichroism | 3 | 0.0 |
DNA Primers | 2 | 0.0 |
Dimerization | 9 | 0.0 |
Mutagenesis | 2 | 0.0 |
Nerve Growth Factors/chemistry/*metabolism | 4 | 57.0 |
Protein Conformation | 9 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Neuropsychological Tests | 2 | 0.0 |
Phosphopyruvate Hydratase/blood | 3 | 20.0 |
Reference Values | 11 | 0.0 |
Risk Factors | 3 | 0.0 |
Age Factors | 2 | 0.0 |
Astrocytes/pathology | 2 | 5.0 |
Calcium-Binding Proteins/*cerebrospinal fluid | 2 | 100.0 |
Cell Death | 2 | 0.0 |
Nerve Growth Factors/*cerebrospinal fluid | 3 | 100.0 |
Immunohistochemistry | 12 | 0.0 |
S100 Proteins/*biosynthesis | 3 | 27.0 |
S100 Proteins/biosynthesis/*physiology | 2 | 100.0 |
Calcium/metabolism | 6 | 0.0 |
Kinetics | 4 | 0.0 |
Time Factors | 15 | 0.0 |
Tumor Cells, Cultured | 11 | 0.0 |
Phosphopyruvate Hydratase/*blood | 4 | 23.0 |
Nerve Growth Factors/blood/*metabolism | 2 | 100.0 |
Calcium-Binding Proteins/chemistry | 3 | 42.0 |
Reproducibility of Results | 6 | 0.0 |
S100 Proteins/*chemistry | 7 | 58.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Cognition | 3 | 5.0 |
Mental Status Schedule | 2 | 6.0 |
Psychiatric Status Rating Scales | 2 | 0.0 |
Biological Markers/blood | 16 | 1.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Nerve Growth Factors/metabolism | 3 | 5.0 |
Prognosis | 17 | 0.0 |
Skin Neoplasms/*metabolism/pathology | 3 | 4.0 |
Calcium-Binding Proteins/*physiology | 3 | 15.0 |
DNA/metabolism | 2 | 0.0 |
Nerve Growth Factors/*physiology | 3 | 6.0 |
*Nuclear Proteins | 2 | 0.0 |
Phosphorylation | 6 | 0.0 |
Rabbits | 4 | 0.0 |
Autoantigens/blood | 2 | 28.0 |
*Schizophrenic Psychology | 2 | 3.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
S100 Proteins/analysis/*metabolism | 2 | 50.0 |
Calcium/*metabolism | 11 | 1.0 |
Cell Differentiation | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Brain/*metabolism | 3 | 0.0 |
Intraoperative Complications/*blood/diagnosis | 2 | 100.0 |
Tissue Distribution | 3 | 0.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Follow-Up Studies | 10 | 0.0 |
Survival Rate | 4 | 0.0 |
Osmolar Concentration | 2 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Mice | 19 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Calcium-Binding Proteins/*metabolism | 3 | 3.0 |
Cell Line | 6 | 0.0 |
Neuroglia/metabolism | 4 | 5.0 |
Zinc/*metabolism | 4 | 6.0 |
Brain/metabolism/pathology | 3 | 2.0 |
Neuroglia/*physiology | 2 | 7.0 |
Biological Markers | 15 | 0.0 |
L-Lactate Dehydrogenase/blood | 4 | 3.0 |
Postoperative Period | 2 | 0.0 |
Brain/*metabolism/pathology/physiopathology | 2 | 10.0 |
S100 Proteins/genetics/*metabolism | 6 | 33.0 |
Up-Regulation/genetics | 2 | 2.0 |
*Cardiac Surgical Procedures | 3 | 6.0 |
Cardiopulmonary Bypass | 4 | 8.0 |
Prospective Studies | 11 | 0.0 |
S100 Proteins/*analysis | 8 | 17.0 |
Sensitivity and Specificity | 11 | 0.0 |
Brain Injuries/*cerebrospinal fluid | 2 | 40.0 |
Glasgow Coma Scale | 2 | 7.0 |
S100 Proteins/*cerebrospinal fluid | 2 | 25.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Treatment Outcome | 6 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Astrocytoma/metabolism | 2 | 8.0 |
COS Cells | 3 | 0.0 |
Gene Library | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
S100 Proteins/chemistry/*metabolism | 3 | 50.0 |
Aging/*physiology | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
S100 Proteins/blood/*cerebrospinal fluid | 2 | 100.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Glial Fibrillary Acidic Protein/metabolism | 3 | 1.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Immunoassay | 6 | 2.0 |
Neoplasm Metastasis | 3 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Recurrence | 3 | 0.0 |
Tumor Markers, Biological/*blood | 6 | 1.0 |
ROC Curve | 3 | 1.0 |
Calcium-Binding Proteins/*genetics | 2 | 2.0 |
Nerve Growth Factors/*genetics | 2 | 3.0 |
S100 Proteins/*genetics | 2 | 10.0 |
Nerve Growth Factors/blood | 3 | 75.0 |
S100 Proteins/blood | 6 | 85.0 |
Cattle | 10 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Infant, Newborn | 10 | 0.0 |
*Cardiopulmonary Bypass | 3 | 3.0 |
Binding Sites/genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/chemistry/*metabolism | 2 | 5.0 |
Structure-Activity Relationship | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Autoantigens/*blood | 2 | 28.0 |
Survival Analysis | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Copper/*metabolism | 2 | 2.0 |
*Protein Structure, Secondary | 2 | 1.0 |
S100 Proteins/*chemistry/*metabolism | 4 | 50.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Transfection | 4 | 0.0 |
*Chromosomes, Human, Pair 21 | 5 | 3.0 |
Down Syndrome/*diagnosis | 3 | 9.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Calcium-Binding Proteins/genetics/*metabolism | 2 | 8.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Apoproteins/chemistry | 4 | 40.0 |
Protein Structure, Secondary | 6 | 0.0 |
Nerve Growth Factors/cerebrospinal fluid | 5 | 71.0 |
Chromosome Mapping | 4 | 0.0 |
Cardiopulmonary Bypass/*adverse effects | 2 | 7.0 |
Actins/genetics | 2 | 1.0 |
Disease Models, Animal | 5 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Temperature | 2 | 0.0 |
Chromosomes, Human, Pair 21/*genetics | 2 | 2.0 |
Gene Amplification | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Cloning, Molecular | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Calcium/*chemistry | 2 | 15.0 |
Calcium-Binding Proteins/*chemistry | 3 | 17.0 |
Nerve Growth Factors/*chemistry | 4 | 36.0 |
Nuclear Magnetic Resonance, Biomolecular | 3 | 1.0 |
*Protein Conformation | 2 | 0.0 |
Sweat Gland Neoplasms/*metabolism/pathology | 2 | 100.0 |
Glasgow Outcome Scale | 2 | 22.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Calcium-Binding Proteins/*analysis | 2 | 15.0 |
Nerve Growth Factors/*analysis | 4 | 26.0 |
*Brain Chemistry | 3 | 1.0 |
Calcium/*pharmacology | 2 | 2.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
In Vitro | 2 | 0.0 |
Astrocytes/metabolism | 2 | 2.0 |
S100 Proteins/*blood/metabolism | 2 | 100.0 |
Molecular Weight | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Proteins/*chemistry | 2 | 2.0 |
Astrocytes/*metabolism | 2 | 3.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mice/*genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Nerve Growth Factors/*biosynthesis | 2 | 14.0 |
Calcium-Binding Proteins/analysis | 2 | 13.0 |
Neurons/*metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Karyotyping | 2 | 0.0 |
Nerve Growth Factors/*urine | 2 | 100.0 |
S100 Proteins/*urine | 2 | 100.0 |
Acute Disease | 3 | 0.0 |
Disease Progression | 3 | 0.0 |
Structural Homology, Protein | 2 | 9.0 |
Levodopa/*blood | 2 | 100.0 |
S100 Proteins/metabolism | 2 | 1.0 |
Tyrosine/*blood | 2 | 5.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Statistics | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
S100 Proteins/*isolation & purification/metabolism | 2 | 100.0 |
*Biological Markers | 3 | 2.0 |
Muscles/*analysis | 2 | 25.0 |
Area Under Curve | 2 | 0.0 |
Linear Models | 2 | 0.0 |
Zinc/metabolism | 2 | 2.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Cohort Studies | 2 | 0.0 |
Postoperative Complications/prevention & control | 2 | 6.0 |
Ultrasonography, Doppler, Transcranial | 2 | 18.0 |
Nerve Growth Factors/*chemistry/*metabolism | 2 | 66.0 |
Solutions | 2 | 1.0 |
Microscopy, Confocal | 2 | 0.0 |
